Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Linde E.M. de Wijs"'
Autor:
Suzanne G.M.A. Pasmans, DirkJan Hijnen, Linde E.M. de Wijs, Marie L A Schuttelaar, Aviël Ragamin, Madelon B. Bronner, Nicolette Arends
Publikováno v:
The Journal of dermatology, 48(12), 1863-1870. Wiley
The Journal of Dermatology
Journal of Dermatology, 48(12), 1863-1870. Wiley-Blackwell
The Journal of Dermatology
Journal of Dermatology, 48(12), 1863-1870. Wiley-Blackwell
The first wave of the coronavirus disease 2019 (COVID‐19) pandemic had an enormous impact on health‐care services, including on care provision for children with atopic dermatitis (AD). We investigated the impact of COVID‐19 on the care for chil
Autor:
A.C.M. Kunkeler, DirkJan Hijnen, Linde E.M. de Wijs, Tamar Nijsten, Jonathan I. Silverberg, José D. van der Waa
Publikováno v:
Clinical and Experimental Allergy, 51(7), 959-967. Wiley-Blackwell Publishing Ltd
Clinical and Experimental Allergy
Clinical and Experimental Allergy
Patch test reactions during dupilumab treatment showed a reproducibility rate of 29%. Reproducibility rates were higher for initially extreme (+++) or strong positive (++) reactions. Patch test reactions might be suppressed during dupilumab treatment
Autor:
Linde E.M. de Wijs, A.L. Bosma, Beau R. van Nieuwenhuizen, Phyllis I. Spuls, DirkJan Hijnen, Michel H. Hof, L.A.A. Gerbens, M.A. Middelkamp‐Hup
Publikováno v:
Journal of the American Academy of Dermatology, 83(5), 1375-1384. Mosby Inc.
Background: Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. Objective: To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment. Method
Autor:
Beau R. van Nieuwenhuizen, M.A. Middelkamp‐Hup, Phyllis I. Spuls, Linde E.M. de Wijs, A.L. Bosma, DirkJan Hijnen, Michel H. Hof, L.A.A. Gerbens
Publikováno v:
Journal of the American Academy of Dermatology, 85(3), e173-e174. Mosby Inc.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9834a7a29da82ec2a6c8c2e8c1926fb1
https://pure.amc.nl/en/publications/response-to-comment-on-longterm-effectiveness-and-safety-of-treatment-with-dupilumab-in-patients-with-atopic-dermatitis-results-of-the-treat-nl-treatment-of-atopic-eczema-the-netherlands-registry(1014f005-ec60-4ae7-ba57-cffc3525cf55).html
https://pure.amc.nl/en/publications/response-to-comment-on-longterm-effectiveness-and-safety-of-treatment-with-dupilumab-in-patients-with-atopic-dermatitis-results-of-the-treat-nl-treatment-of-atopic-eczema-the-netherlands-registry(1014f005-ec60-4ae7-ba57-cffc3525cf55).html